Joe Basil's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q1 2016
Question
Joe Basil of Catalyst Capital questioned the decision to end the PV-10 expanded access program, asking if it was to focus resources on core trials. He also inquired about the data timeline for the PV-10/radiation combination study, potential resource diversion by MOA trials, the global expansion of the Phase 3 trial, and the potential for multiple presentations at the upcoming ASCO meeting.
Answer
CTO Eric Wachter confirmed the expanded access program is closing to focus human and capital resources on core pivotal trials and meet stricter Phase 3 regulatory requirements. He assured that results from the radiation combination study are expected and that MOA clinical activities are not diverting resources. He also detailed the strategy for global expansion via lead regional investigators. Interim CEO Peter Culpepper added that information on ASCO presentations would be released soon.